30 April 2025
Topcon brought the eye-light device for the treatment of dry age-related macular degeneration (AMD) to 100% Optical (1–3 March).
The technology, from Espansione Group, uses photobiomodulation, or low-level light therapy, for the treatment of dry-AMD, seeking to slow the progression of the disease.
Fergal Byron, senior technical product manager at Topcon Healthcare Europe, described the device as: “Revolutionary, in terms of the treatment of a disease that up until now there has been no treatment for other than dietary changes or taking supplements.”
The eye-light device is already being used in practice to deliver dry eye treatments using low level light therapies (LLLT) and intense pulsed light therapies. New clearance means AMD is now included in the range of uses for the device.
The non-invasive treatment requires a combination of yellow and red masks at different light wavelengths, with a follow-up six months later.
Practices incorporating the device into practice may wish to run specific clinics dedicated to this type of treatment, Byron suggested.
“Customers implementing this need to devise the different journey for these patients and dedicate the time and space in the practice to deliver the treatment,” he said.
The launch followed the publication of six-month results from the Drusen Study, part of the LightWave I research into the effects of light modulation LLLT for patients with dry AMD.
The double-blind, randomised trial encompassed data from more than 150 eyes, with Byron explaining that the results indicated a slowing of the progression of the drusen and an improvement in best-corrected visual acuity by five or more letters on LOGMAR.
The study is part of an ongoing longitudinal multicentre trial.
Comments (0)
You must be logged in to join the discussion. Log in